Switzerland fast-tracks antiviral medication against Covid-19
Remdesivir has already been granted temporary approval in other countries.
Keystone / Marcel Kusch
The Swiss health authorities have granted approval for the remdesivir drug in “record time” for treating coronavirus patients. The temporary authorisation to widen the use of the antiviral drug will be closely monitored in case of adverse side effects.
This content was published on
2 minutes
swissinfo.ch/mga
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday.
It can now be used for a limited period of time to treat patients suffering from SARS-CoV-2-related pneumonia who also require oxygen.
The drug has been authorized for emergency use in the United States, India, Singapore, South Korea and Japan and has been recommended by the European Medicines Agency to treat coronavirus patients in the EU.
Swissmedic said on Thursday that it had conducted a “careful review in record time” of the drug. Hospital doctors have now been given the green light to administer the treatment. “Adverse reactions to the drug will be closely monitored in order to ensure patient safety,” read a statement.
“The product will also be made available to patients outside approved clinical trials and the approved compassionate use programme while the submitted authorisation application is being reviewed,” it added.
Clinical trials in the US on medicaments containing the active ingredient remdesivir found that the hospital stay of severely affected Covid-19 patients was shortened in almost a third of cases.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
EU Commission president says Swiss-EU deal is ‘historic’ agreement
This content was published on
At a joint media conference with Swiss President Viola Amherd in Bern, European Commission President Ursula von der Leyen spoke of a "day of joy".
Switzerland and EU reach deal on future bilateral relations
This content was published on
Switzerland and the European Union have announced a political agreement to update their trading relationship after almost a decade of difficult talks.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Sixteen Swiss hospitals take part in coronavirus global Solidarity trial
This content was published on
Some 1,000 patients in Switzerland are expected to participate in trials of experimental treatments for Covid-19 as part of global Solidarity trial.
Fight over rights to Covid-19 drugs puts Switzerland in a tough spot
This content was published on
As calls mount for equitable access, Switzerland is caught between established practice and global solidarity in how to encourage medical innovation.
This content was published on
Swiss scientists and drug companies are playing an important role in the global effort to develop treatments or a vaccine for the virus.
Swiss hospitals launch drug trial to prevent Covid-19 infection
This content was published on
Researchers in Geneva and Basel have launched a clinical trial to test two drugs on people that have been in contact with Covid-19 patients.
Novartis steps up coronavirus fight as part of new collaboration
This content was published on
Several big pharmaceutical companies have joined forces with the Bill & Melinda Gates Foundation in response to the coronavirus pandemic.
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
Covid-19 is both threat and opportunity for Swiss biotech
This content was published on
Although the coronavirus pandemic is the Swiss biotech industry’s time to shine, it has left many smaller firms struggling to survive.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.